Reduction of opioid and barbiturate use following initiation of rimegepant for migraine in the United States

Documents similaires

• Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine
  par: Jessica Ailani, et autres
  Publié: (2024)
• A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine
  par: David Kudrow, et autres
  Publié: (2025)
• Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose‐ranging, double‐blind, randomized controlled trial
  par: Koichi Ikeda, et autres
  Publié: (2025)
• Efficacy and safety of rimegepant for the acute treatment of migraine in Black or African American adults: A post hoc pooled subgroup analysis from three randomized, placebo‐controlled clinical trials
  par: Larry Charleston, et autres
  Publié: (2026)
• A phase 1, multicenter, open‐label study to evaluate the pharmacokinetics, safety, and tolerability of a single dose of rimegepant in children (aged ≥6 to <12 years) with a history of migraine
  par: Chay Ngee Lim, et autres
  Publié: (2025)